Get the Daily Brief
Latest Biotech News
SpatialBench: benchmark exposes agents’ gaps on real spatial biology tasks
SpatialBench, a new benchmark suite, evaluates agent‑based tools on realistic spatial biology analysis workflows and reveals performance gaps between demo scenarios and deployment‑grade tasks. The...
Microbiota signature links breast, colorectal and lung cancers
A multicancer study mapped tumor‑associated microbiota and found overlapping microbial signatures across breast, colorectal and lung cancers. The multidisciplinary team reported conserved taxa and...
CMS rolls out Medicare GLP‑1 model: voluntary expansion of coverage
CMS launched a voluntary payment model to expand Medicare coverage of GLP‑1 weight‑loss drugs, aiming to broaden beneficiary access while testing new payment and utilization rules. The program,...
FDA greenlights Yartemlea – first therapy for fatal stem‑cell transplant complication
The FDA approved Omeros’s complement inhibitor Yartemlea as the first approved therapy for a severe and potentially fatal complication of hematopoietic stem cell transplants. Omeros secured...
J&J shelves eczema asset from $1.25B deal: efficacy fails company bar
Johnson & Johnson said it will discontinue development of the experimental eczema drug JNJ‑5939 (NM26), the asset it acquired for $1.25 billion in 2024, after the program failed to meet internal...
Biohaven’s potassium‑channel candidate fails Phase 2 – second mid‑stage setback
Biohaven reported that its potassium‑channel modulator missed primary endpoints in a Phase 2 trial for major depressive disorder, marking a second mid‑stage failure for the program. The company...
Tumor‑sensing AAVs: design framework aims to sharpen gene delivery
Researchers unveiled an intelligent design framework for adeno‑associated virus (AAV) vectors that respond to tumor microenvironment cues to improve targeting and infiltration into tumors. The...
Nanovaccines for HCC: engineered nanoparticles enter immunotherapy playbook
A new body of work positioned nanovaccine platforms as next‑generation immunotherapies for hepatocellular carcinoma (HCC), detailing nanoparticle formulations that deliver tumor antigens and...
SpatialBench: benchmark forces biology agents out of demo mode
SpatialBench introduced a suite of 146 verifiable problems drawn from real spatial biology workflows to benchmark agents that analyze spatial transcriptomics and imaging data. The authors argue...
CAR‑T neurotoxicity: new findings refine safety profile and monitoring
New research delivered fresh mechanistic and clinical insights into neurotoxic events associated with CAR‑T cell therapies, identifying pathways and biomarkers linked to neurological adverse...
PLGA‑encapsulation of cisplatin+silibinin enhances cervical cancer response
Akbari and colleagues reported that co‑encapsulating cisplatin with the natural compound silibinin in biodegradable PLGA nanoparticles improved tumor uptake and anti‑cancer efficacy in preclinical...
Targeted protein degradation: therapeutic promise with ecological caveats
A review explored targeted protein degradation (TPD) as a transformative therapeutic modality while flagging potential broader biological and ecological impacts. Authors (Yue, He, Hou et al.)...
CMS launches Medicare GLP‑1 model: voluntary pilot to widen access
CMS launched a voluntary payment model intended to expand Medicare coverage of GLP‑1 weight‑loss drugs for eligible beneficiaries. The administration designed the pilot to test payment approaches...
FDA greenlights therapy for fatal transplant complication: first approved option
The FDA approved Yartemlea, Omeros’s complement‑system drug, for a severe and potentially fatal complication of hematopoietic stem cell transplants, marking the first regulator‑confirmed therapy...
J&J axes eczema drug — $1.25B acquisition bet fails after Phase 2 miss
Johnson & Johnson terminated development of its experimental eczema candidate JNJ‑5939 (NM26) after a Phase 2 trial did not meet efficacy thresholds, ending hopes tied to the $1.25 billion...
Engineered AAVs sense tumors: new vectors aim for precision delivery
Researchers published a framework for engineering adeno‑associated virus (AAV) vectors that dynamically respond to features of the tumor microenvironment to enhance tumor targeting and...
Nanovaccines enter HCC immunotherapy pipeline: targeted antigen delivery advances
Researchers reported progress on nanovaccine platforms tailored to hepatocellular carcinoma (HCC), demonstrating nanoparticle‑mediated antigen presentation and immune activation in preclinical...
SpatialBench benchmark: testing agents on real spatial biology workflows
SpatialBench, a new benchmark suite, evaluates computational agents on 146 verifiable spatial biology problems drawn from real analysis workflows across five platforms (Vizgen MERFISH, 10x Visium,...
CAR‑T neurotoxicity insights sharpen: new data on mechanisms and management
Recent advances summarize mechanisms behind CAR‑T cell therapy neurotoxicity, consolidating clinical signals, imaging correlates, and biomarker profiles to refine risk stratification and...
New strategies to overcome lung cancer drug resistance: emerging combos and targets
Researchers reported therapeutic approaches aimed at reversing multidrug resistance (MDR) in lung cancer, including novel small molecules, combination regimens, and delivery systems that restore...